MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Behavioral abnormalities"

  • 2024 International Congress

    Visual Temporal Discrimination Threshold using a Virtual Reality Paradigm in Cervical Dystonia

    SR. Bostan, B. Lim, C. Fearon, R. Reilly (Dublin, Ireland)

    Objective: To develop a Virtual Reality (VR) application to test temporal discrimination thresholds in cervical dystonia patients within an outpatient environment. Background: Temporal discrimination threshold…
  • 2024 International Congress

    Dysfluent Writing Behavior Associates with Reduced Striatal-cerebellar Connectivity in Writer’s Cramp Dystonia

    Z. Simsek, M. Lipp, S. Groves, Z. Huang, M. Fei, J. Voyvodic, C. Petty, M. Lutz, N. Bukhari-Parlakturk (Durham, USA)

    Objective: The primary objective of this study was to identify the brain regions contributing to dysfluent writing behavior in a subtype of dystonia called writer’s…
  • 2024 International Congress

    Study of Relationship Between Homocysteine, Folic Acid And Vitamin B12 Levels In Serum of Juvenile HD Children.

    A. Kumar, P. Mishra (Delhi, India)

    Objective: Our objective is to estimate the level of Hcy ,vitamin B12 , folic acid with motor and non-motor symptoms in HD patients in school…
  • 2024 International Congress

    Clinical and Epidemiological Aspects of Neuropsychiatric Features in Patients with Huntington Disease in Chile

    J. Fuentes, P. Salles, P. Chaná-Cuevas, C. Montalva, M. Sánchez, N. Rojas (Santiago, Chile)

    Objective: To describe the prevalence of motor and neuropsychiatric symptoms in HD patients seen at the Center of Movement Disorders (CETRAM), Santiago, Chile. Background: There…
  • 2024 International Congress

    Clinico- radiological profile of four patients with CSF1R- related leukoencephalopathy: A case series from India

    R S. Harishma, N. Kamble, P. Pal, V V. Holla, R. Yadav, S. Prasad (Bengaluru, India)

    Objective: We aimed to describe the clinical, radiological and genetic profile of patients with CSF1R- related leukoencephalopathy. Background: CSF1R- related leukoencephalopathy is a rare dominantly…
  • 2023 International Congress

    Severe movement disorder initially suspected of being conversion – key insights from the psychiatrist

    L. Jaffe (Honolulu, USA)

    Objective: The review of a case diagnosed as Conversion Disorder (CD) in a University Movement Disorders clinic is presented here.  As this patient eventually recovered…
  • 2023 International Congress

    Genetic and psychiatric risk factors for impulse control disorders in de novo Parkinson’s disease

    M. Ruitenberg, E. Whooley, H. Macdonald, V. Koppelmans (Leiden, Netherlands)

    Objective: To assess the interplay of polygenic dopamine risk scores and psychiatric symptoms in the development of impulse control disorders (ICDs) in de novo patients…
  • 2023 International Congress

    Self-report vs. informant-report of problematic behaviors using the Huntington’s Disease-Behavioral Questionnaire

    S. Hughes, E. Churchill, G. Parkin, B. Culbert, A. Smirnova, A. Hall, P. Gilbert, J. Corey-Bloom (San Diego, USA)

    Objective: To examine the utility of a new behavioral measure, the Huntington’s Disease–Behavioral Questionnaire (HD-BQ) (Hughes et al, 2023), in individuals with Huntington’s disease (HD).…
  • 2023 International Congress

    Impact of dopamine replacement therapy on shame in Parkinson’s disease patients

    S. Catalano Chiuvé, D. Benis, A. Zulet, P. Krack, V. Fleury (Geneva, Switzerland)

    Objective: This study aims to investigate the effect of dopaminergic replacement therapy (DRT) on shame using emotional dynamic rating scales during ON and OFF-DRT states.…
  • 2023 International Congress

    Evaluating the efficacy of dextromethorphan/quinidine (DM/Q) in treating irritability in Huntington’s disease

    E. Furr Stimming, S. Abdollah Zadegan, J. Patino, N. Rocha (Houston, USA)

    Objective: To prove the efficacy and safety of dextromethorphan/quinidine 20mg/10mg (Nuedexta®) in patients with irritability due to HD. Background: Irritability is one of HD's most…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 16
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley